FDA Review and Meeting Minutes Search
Before approving a drug, FDA's scientists write long reviews of the evidence, and its meetings with the company along the way are minuted. FDA publishes both after approval; this searches their full text.
Search what FDA's reviewers wrote about novel drugs and biologics, most approved since 2015: the clinical, statistical, pharmacology/toxicology and clinical pharmacology reviews in each Drugs@FDA approval package, and the minutes of the sponsor's meetings with FDA filed with them. Each result opens FDA's PDF at the page.
- Approval packages: 797
- Documents with text: 4,585
- Searchable pages: 335,761
- Meeting minutes pages: 19,263
Start with a question
Searches regulatory teams run on FDA's past reviews. Each opens its results.- All documentscarcinogenicity waiverWhen FDA agreed a rodent carcinogenicity study was not needed
- Statistical review"non-inferiority margin"How statistical reviewers judged the margin
- Meeting minutes"chronic toxicity" durationWhat FDA told sponsors about long-term toxicity studies
- Meeting minutes"end of phase 2" dose selectionDose-finding advice at end-of-phase-2 meetings
- All documents"single adequate and well-controlled" confirmatory evidenceApprovals on one trial plus confirmatory evidence
- Clinical pharmacology reviewQT prolongation thorough QT waiverWhen a thorough QT study was not required
Approval packages in the index
Novel drug and biologic approvals whose review documents are searchable, by approval year, 2000 to Sep 25, 2026, plus 79 older packages.
How to read this
A hatched bar is a year that is not over, so its count covers only part of the year.
- Full year
- 2026 to date
FDA's review PDFs for approvals from Jan 4, 1972 to Sep 25, 2026, read page by page from their text layer and refreshed weekly. Scanned pages without text are not searched. Drugs@FDA approval packages
About this search
What is searched
Every review file in the approval package: the clinical (medical) review; the statistical review; the nonclinical (pharmacology/toxicology) review; the clinical pharmacology review; the summary, cross-discipline team leader and office director reviews, and since 2019 the integrated or multi-discipline review that combines them; and product quality, microbiology, risk management, other reviews and the administrative and correspondence file. Approval letters, labels and proprietary name reviews are left out.
Pages in the correspondence files that are FDA's minutes of a meeting with the sponsor, from the “Memorandum of Meeting Minutes” heading to the electronic signature page, are marked as meeting minutes and labelled with the meeting (pre-IND, end of phase 2, pre-NDA, pre-BLA or the meeting type).
How to search
Words are matched in any form (dose, doses, dosing). Put a phrase in quotes to match it exactly, write or between alternatives (“carcinogenicity or carcinogenic”), and put a minus before a word to leave out pages that use it.
Frequently asked questions
- Where are the meeting minutes from?
- FDA does not publish meeting minutes on their own. When it posts an approval package on Drugs@FDA, the Administrative and Correspondence Documents (and sometimes Other Reviews) file often includes FDA's minutes of the sponsor's pre-IND, end-of-phase-2, pre-NDA or pre-BLA meetings, with FDA's written answers to the sponsor's questions. This search marks those pages as meeting minutes.
- Which approvals are covered?
- Novel drugs (NDAs for new molecular entities, chemical type 1) and original BLAs whose approval package FDA has posted, most approved since 2015 with some older packages. Supplements, generics and other new NDAs are not included yet.
- Why is a document I expect missing?
- FDA posts packages months after approval and redacts parts of them. Some older packages are scanned images with no text layer; those pages cannot be searched until they are read with OCR, which this search does not do yet.
- How are results ranked?
- By Postgres full-text relevance: how often and how close together the search words appear on a page. Each document shows its best-matching page, with the number of other matching pages.